Poniard Pharmaceuticals (Poniard Pharmaceuticals) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Apr. 29, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Poniard Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Poniard Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Poniard Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Poniard Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poniard Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

Poniard Pharmaceuticals (OTCPK:PARD) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Poniard Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119

Website

http://www.poniard.com

Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.

Executives

Michael S Perry	officer: President & CMO	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell	director, officer: Chief Executive Officer	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer	director	161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver	officer: Chief Financial Officer	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler	10 percent owner	801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc	10 percent owner	C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines

From GuruFocus

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-12-2009

Poniard Pharmaceuticals Inc. (PARD) CFO Gregory L Weaver buys 3,000 Shares

By GuruFocus Research GuruFocus Editor • 08-22-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-06-2009

Poniard Pharmaceuticals Inc. (PARD) CFO Gregory L Weaver buys 2,000 Shares

By gurufocus • 04-06-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-09-2010

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-07-2009